PMC7390838_01
T2-weighted basal sagittal pituitary MRI performed at diagnosis. The red arrow indicates the sellar mass.
fendo-11-00471-g0001.jpg
PMC7390838_01_fendo-11-00471-g0001.jpg
F1
T2-weighted sequences with an inhomogeneous contrast distribution due to the presence of internal colliquative areas (Figure 1).
Imaging performed 3 months after surgery. (A,B) Pituitary MRI, T2-weighted basal sagittal and coronal sequences. (C,D) Pituitary MRI, T1- weighted post-gadolinium sagittal and coronal sequences. (E) Whole body fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) showing pathological uptake in sellar region. Red arrows indicate the sellar lesion.
fendo-11-00471-g0002.jpg
PMC7390838_01_fendo-11-00471-g0002.jpg
F2
No other areas of increased uptake were identified (Figure 2).
Pituitary MRI performed after combined therapy with dabrafenib and trametinib, showing the complete remission of the pituitary mass. (A,B) T2-weighted basal sagittal and coronal sequences. (C,D) T1- weighted post-gadolinium sagittal and coronal sequences MRI.
fendo-11-00471-g0003.jpg
PMC7390838_01_fendo-11-00471-g0003.jpg
F3
After 6 months of therapy, a pituitary MRI showed complete remission (CR) of the disease with no evidence of the mass in the sellar region (Figure 3).